Table 2 Rituximab treatment details and responses
From: Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy
Case | Indication | Rtx induction dosage | Rtx maintenance dosage | ERG response | Visual field after Rtx | OCT of the macula | Visual acuity | Atb results before Rtx | Atb results after Rtx/time when sample was collected | Outcome after Rtx | Follow up after Rtx (m) | Rtx stopped because of side effects |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Failure on other tx after initial response | 1000Â mg X1 | 1000Â mg, 2Â month intervals, (total 11 doses) | 30Â Hz flicker stable | Stability | Improvement in macular edema at 14Â months | Stable | 45, 50, 56 | Absence/(14Â months on Rtx) | Stable | 14 | No |
2 | No response to other tx | 375Â mg/m2 (750Â mg), 4 doses at one week intervals | Same regiment 6Â months later | Deterioration | Decreased sensitivity | Progression, increased granularity OD, CRAO OS | Stable | 36, 40, 46 (enolase), 68 | 46 (enolase) (level unknown)/10Â months on Rtx | No response | 15 | No |
3 | No previous tx | 675Â mg/m2 (1000Â mg), 2 doses at one month intervals | - | Deterioration | Not performed | No change | Decreased | 23 (HSP27), 28, 34, 36, 39, 46 (enolase), 62 | 23 (HSP27), 28, 34, 36, 39, 46 (enolase), 62 (same level than before)/5Â weeks on Rtx | No response | 6 | No |
4 | Failure on other tx after initial response | 750Â mg/m2 (1000Â mg), 2 doses at 1Â week intervals | Same regiment 13Â months later | Every response improved except flicker | Improved | Increased granularity OD, unchanged OS | Improved 1 line OU | Absent after first trial of immuno-therapy | - | Improved | 17 | No |
5 | Failure on other tx | 375Â mg/m2 (635Â mg), 4 doses at one week intervals | Same regiment 12Â months later | Response to rechallenge | Slightly improved | Unchanged, no macular edema | Unchanged | 42,45,62, 74 | 42,45,74 (same level than before)/5Â months on Rtx | Stable | 21 | Yes |